Panes, Julian
Otley, Anthony
Sanchez Gonzalez, Yuri
Fitzgerald, Kristina
Zhou, Wen
Ilo, Dapo
Brion, Triza http://orcid.org/0000-0002-5512-5420
Tahir, Muna J.
Funding for this research was provided by:
AbbVie
Article History
Received: 6 October 2022
Accepted: 19 December 2022
First Online: 11 February 2023
Declarations
:
: Julian Panes received financial support for research from AbbVie and Pfizer; received lecture fee(s) from AbbVie, Ferring, Janssen, Takeda; and received consultancy fees from AbbVie, Arena Pharmaceuticals, Athos, Boehringer Ingelheim, Celltrion, Ferring, Galapagos, Genentech, GSK, Janssen, Mirum Pharma, Morphic Therapeutic, Origo, Pandion, Pfizer, Progenity, Robarts, Roche, Takeda, Theravance, and Wassermann. Anthony Otley receives financial support for research from AbbVie; serves on Advisory Board for AbbVie Canada, Janssen Canada; is site investigator for clinical trials for AbbVie, Pfizer, and Eli Lilly. Yuri Sanchez Gonzalez, Kristina Fitzgerald, Wen Zhou, and Dapo Ilo are full-time employees of AbbVie and may hold AbbVie stock and/or stock options. Triza Brion and Muna J. Tahir are full-time employees of ICON and received consultancy fees from AbbVie.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by Salus IRB (May 26, 2016/Protocol No. 8001-0424).
: Ethical approval was obtained from central Ethics Committees for both Part 1 and 2 of the study (Salus IRB, Austin, TX), and the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.
: Informed consent was obtained from all individual participants included in the study.